Cheng Isaac's Form 4 filing
Amylyx Pharmaceuticals, Inc. (AMLX) · filed Jan 10, 2022
- Accession no.
- 0000899243-22-001525
- Filed
- Jan 10, 2022
- Trade date
- Jan 6, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 5 derivative transactions. Open-market purchases total $125.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cheng IsaacCIK 0001829696 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 6, 2022 | Common Stock | CConversionAcquired | +1,409,035 | –F1 | – | 1,409,035 | Indirect | |
| Jan 6, 2022 | Common Stock | CConversionAcquired | +6,410,964 | –F1 | – | 7,819,999 | Indirect | |
| Jan 6, 2022 | Common Stock | CConversionAcquired | +974,107 | –F1 | – | 8,794,106 | Indirect | |
| Jan 6, 2022 | Common Stock | CConversionAcquired | +1,621,544 | –F1 | – | 10,415,650 | Indirect | |
| Jan 6, 2022 | Common Stock | PPurchaseAcquired | +6,578 | $19.00 | +$124,982 | 6,578 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 6, 2022 | Common Stock | CConversionDisposed | −1,409,035 | $0.00 | $0 | 0 | Indirect | |
| Jan 6, 2022 | Common Stock | CConversionDisposed | −6,410,964 | $0.00 | $0 | 0 | Indirect | |
| Jan 6, 2022 | Common Stock | CConversionDisposed | −974,107 | $0.00 | $0 | 0 | Indirect | |
| Jan 6, 2022 | Common Stock | CConversionDisposed | −1,621,544 | $0.00 | $0 | 0 | Indirect | |
| Jan 6, 2022 | Common Stock | AGrant or awardAcquired | +8,400 | $0.00 | $0 | 8,400 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date.
Referenced by the price of 4 transactions in Table I.